Table 1.

Summary of genetic alterations detected in brain metastases and corresponding short-term cultures of five patients. The respective mutant allele frequencies are indicated in brackets

Sample ID	Primary tumor entity	DNA variants detected in BM tissue samples	DNA variants detected in BM-derived short-term cultures
BM28	NSCLC	STK11 c.289_290 + 2delAAGT (AF = 59.6%) TP53 c.734G > T:p.G245V (AF = 69.8%)	STK11 c.289_290 + 2delAAGT (AF = 90.5%) TP53 c.734G > T:p.G245V (AF = 92.5%)
BM31	Melanoma	KIT c.2447 A > T:p.D816V (AF = 29.5%) JAK3 c.2164G > A:p.V722I (AF = 50.1%)	KIT c.2447 A > T:p.D816V (AF = 31.7%) JAK3 c.2164G > A:p.V722I (AF = 51.0%)
BM32	GC	ATM c.2572T > C:p.F858L (AF = 40.8%)	ATM c.2572T > C:p.F858L (AF = 44.3%)
BM35	NSCLC	FGFR3 c.1345 C > T:p.P449S (AF = 49.1%) KRAS c.34G > T:p.G12C (AF = 50.9%)	FGFR3 c.1345 C > T:p.P449S (AF = 52.6%) KRAS c.34G > T:p.G12C (AF = 62.8%)
BM36	ESCA	JAK3 c.2152G > C:p.V718L (1st BM: AF = 31.6%; 2nd BM: AF = 36.5%)	JAK3 c.2152G > C:p.V718L (AF = 47.5%)

Abbreviations: NSCLC, non-small cell lung cancer; GC, gastric cancer; ESCA: esophageal carcinoma; AF, mutant allele frequency; BM, brain metastasis